2Q5 Stock Overview
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renovaro Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$4.84 |
| 52 Week Low | US$0.22 |
| Beta | 0.43 |
| 1 Month Change | -55.02% |
| 3 Month Change | -42.50% |
| 1 Year Change | 11.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2Q5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -24.3% | -2.9% | 1.9% |
| 1Y | 11.2% | -25.4% | 5.9% |
Return vs Industry: 2Q5 exceeded the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 2Q5 exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 2Q5 volatility | |
|---|---|
| 2Q5 Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2Q5's share price has been volatile over the past 3 months.
Volatility Over Time: 2Q5's weekly volatility has decreased from 35% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Mark Dybul | renovarobio.com |
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells.
Renovaro Inc. Fundamentals Summary
| 2Q5 fundamental statistics | |
|---|---|
| Market cap | €154.32m |
| Earnings (TTM) | -€38.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.0x
P/E RatioIs 2Q5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2Q5 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.23m |
| Earnings | -US$41.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 16.5% |
How did 2Q5 perform over the long term?
See historical performance and comparison